Abstract:The presence of EGFR activating mutations and ALK chromosomic rearrangements with corresponding tyrosine kinase inhibitors (TKIs) has revolutionized the treatment strategies of patients with non-small cell lung cancer (NSCLC). Although tremendously initial response and manageable toxicity profiles, acquired resistance inevitably develops after approximately 1 year treatment with EGFR-TKIs (erlotinib and gefitinib) and ALK inhibitor (crizotinib). Encouragingly, third-generation EGFR-TKIs including AZD9291, CO1686 and brigatinib have showed striking efficacy overcoming acquired resistance driven by T790M secondary mutations. Other novel third-generation EGFR-TKIs such as ASP8274, EGF816, PF-06747775 and avitinib are also being investigated in early-stage clinical trials and the survival and safety data will be released in the near future. Another promising novel EGFR-TKI, namely AZD3759 has showed promising response in patients with brain metastases and leptomeningeal disease. Recently, EAI045, an EGFR allosteric inhibitor, in combination with cetuxmab exhibit antitumor activity in mouse models of lung cancer driven by L858R/T790M/C797S, a resistant mutation of AZD9291. Meanwhile, second-generation ALK inhibitors (ceritinib and alectinib) have entered clinical applications for NSCLC patients with ALK rearrangements after failure of crizotinib and third-generation ALK inhibitors (lorlatinib and ASP3026) are also being evaluated in clinical trials overcoming known ALK resistant mutations. On the other hand, with the development of high-throughput sequencing, called next-generation sequencing (NGS) and genomic technologies, more novel molecular targets such as MET 14 exon skipping splicing mutations have been identified as potential therapeutic targets and simultaneously analyzing hundreds of molecular alterations have turned out reality with limited tumor tissues. In the recent years, the emergence of numbers of oncogenic drivers other than EGFR mutations and ALK rearrangements has divided NSCLC into multiple distinct subtypes amenable to corresponding targeted therapy. For instance, dabrafenib either as monotherapy or in combination with MEK inhibitor (trametinib) has displayed promising antitumor activity and manageable safety profile in patients with BRAF V600E mutations, accounting for around 1.4% of patients with NSCLC. Other novel molecular targets maybe serving as oncogenic drivers including mutations in HER2 (neratinib and pyrotinib) and PI3KCA (BKM120 and GDC0941), ROS1 (entrectinib, foretinib and lorlatinib), RET (XL184) and NTRK (entrectinib) rearrangements and FGFR1 gene amplification (AZD4547, Lenvatinib and FP-1039) are being evaluated either in preclinical settings or early-stage clinical trials. Section not applicable Section not applicable Section not applicable

Emerging Roles of Targeted Small Molecule Protein-Tyrosine Kinase Inhibitors in Cancer Therapy

Tyrosine kinase inhibitors: a clinical perspective

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Kinase-targeted cancer therapies: progress, challenges and future directions

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects

Advances in Small-Molecule Inhibitors of Protein Tyrosine Kinases

The Progress of Tyrosine kinase Inhibitors in Cancer Therapy

Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy

Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors

Multi-targeted Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer: an Era of Individualized Therapy.

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy

Tyrosine kinase inhibitors in cancers: Treatment optimization - Part I

Tyrosine kinase inhibitors in cancer treatment (Part II)

PUB007 Novel TKIs in Non-Small Cell Lung Cancer

Small Molecules Targeting Phosphoinositide 3-Kinases

Targeting cancer with small molecule kinase inhibitors

A review on tyrosine kinase inhibitors for targeted breast cancer therapy

From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond

Trends in kinase drug discovery: targets, indications and inhibitor design

Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia